Enhertu approved in the US as the first HER2-directed therapy for patients with previously treated HER2-mutant metastatic non-small cell lung cancer

Based on DESTINY-Lung02 results which showed AstraZeneca and Daiichi Sankyo’s Enhertu reported a confirmed objective response rate of 57.7% in patients with HER2-mutant disease

Tetra Bio-Pharma secures $6,000,000 financing from Alpha Blue Ocean

MoU signed between Ministry of Ayush and MeitY

MeitY will provide technical support for digitalisation of the Ayush Sector under the Ayush Grid project for a period of three years

Hikal shows 17% degrowth in Q1 FY23

Pharmaceutical sales de-grew 18% YoY and stood at Rs. 224 crore whereas Crop Protection sales de-grew by 15% at Rs. 154 crore

IOL Chemicals and Pharmaceuticals reports Q1 FY23 revenue of Rs. 570.2 Cr

The company will strengthen its position in the ‘green solvent’ market by increasing its capacity by 20% to 120,000 MTPA from 100,000 MTPA before the end of current fiscal

Apollo Hospitals posts Q1 FY23 consolidated PAT at Rs. 317.11 Cr

Apollo Hospital Group completed the acquisition of a hospital asset in Gurugram for a consideration of around Rs 450 crore.

ShilpaMedicare Q1FY23 consolidated PAT drops to to Rs. 84.85 lakhs

Kaléo announces appointments and new government business unit

Aurobindo Pharma posts consolidated Q1FY23 PAT of Rs. 520.54 Cr

The company has reported total income of Rs. 6276.54 crores during the period ended June 30, 2022.

S. Sridhar resigns as Managing Director of Pfizer

Sridhar will continue to serve in his current position of Managing Director for as long a period as required until the identification, selection and transition to the new leadership takes place in the company.